Latest Breaking News On - Nantahala capital partners - Page 1 : comparemela.com

Labaton Sucharow LLP Announce Notice of Pendency and Proposed Settlement For All Record Holders and Beneficial Owners of QAD Inc Class A Common Stock

Labaton Sucharow LLP Announce Notice of Pendency and Proposed Settlement For All Record Holders and Beneficial Owners of QAD Inc Class A Common Stock
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

State of delawareUnited statesNew castle countyNed weinbergerPamelam lopkerAnton chiltonScottj adelsonKathleenm cruscoPaulj fioravanti jrThoma bravoOffice of the register in chanceryQuick parentLabaton sucharowNet settlement fundNantahala capital partners ii limited partnership plaintiffLeonardl williams justice center

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoShalabh guptaGaurav aggarwalRosalind advisors incDrug administrationLogos capitalNantahala capital partnersRosalind advisorsVivo capitalNew drug applicationPhones only

Unicycive Therapeutics, Inc (UNCY) Enters Up to $130M Financing to Commercialize and Launch Investigational New Drug Renazorb

Unicycive Therapeutics, Inc (UNCY) Enters Up to $130M Financing to Commercialize and Launch Investigational New Drug Renazorb
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesShalabh guptaAnne marie fieldssternGaurav aggarwalDrug administrationCompany or unicyciveExchange commissionMaxim groupRosalind advisors incUnicycive therapeutics incCompany seriesa convertible preferred stockWall streetVivo capitalLogos capitalNantahala capital partnersRosalind advisors

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb

06.03.2023 - $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and supported by existing investors Nantahala Capital . Seite 1

Shalabh guptaGaurav aggarwalCompany or unicyciveRosalind advisors incUnicycive therapeutics incDrug administrationVivo capitalLogos capitalNantahala capital partnersRosalind advisorsManaging directorUnicycive boardNew drug applicationChief executive officer

Soleno Therapeutics, Inc announced that it expects to receive $59 89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L P

Soleno Therapeutics, Inc. announced it has entered into a securities purchase agreement for a private placement of 22,600,000 common shares at a price of $2.65 per share for gross proceeds $59,890,000. |

Manish bhatnagarJames mackanessSoleno therapeutics incBlackwell partnersVivo capitalDrug administrationNantahala capital managementSoleno therapeuticsAbingworth bioventuresNantahala capital partnersPinehurst partnersNc stock exchangePress releaseRoceeds slno us8342033094